However, most tumors inevitably develop acquired resistance to EGFR TKIs over time, which limits the benefits of patients and makes patients eventually undergo disease progression.[6,7] How to make rational administration of drug therapy, such as the combination of drugs to reduce the occurrence of drug resistance, the indication of continuing the original TKI or dressing change treatments after drug resistance, is our grand challenges in tumor therapy. This evidence concerns the gene EGFR and neoplasm.